[1]

Baria K, De Toni EN, Yu B, Jiang Z, Kabadi SM, et al. 2022. Worldwide Incidence and Mortality of Biliary Tract Cancer. Gastro Hep Advances 1:618−626

doi: 10.1016/j.gastha.2022.04.007
[2]

Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. 2021. Biliary tract cancer. The Lancet 397:428−444

doi: 10.1016/S0140-6736(21)00153-7
[3]

Scott AJ, Sharman R, Shroff RT. 2022. Precision Medicine in Biliary Tract Cancer. Journal of Clinical Oncology 40:2716−2734

doi: 10.1200/JCO.21.02576
[4]

Oh DY, He AR, Bouattour M, Okusaka T, Qin S, et al. 2024. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. The Lancet Gastroenterology & Hepatology 9:694−704

doi: 10.1016/S2468-1253(24)00095-5
[5]

Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, et al. 2023. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 401:1853−65

doi: 10.1016/S0140-6736(23)00727-4
[6]

Chen X, Wu X, Wu H, Gu Y, Shao Y, et al. 2020. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Journal for Immunotherapy of Cancer 8(2):e001240

doi: 10.1136/jitc-2020-001240
[7]

Yang X, Lian B, Zhang N, Long J, Li Y, et al. 2024. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. BMC Medicine 22:42

doi: 10.1186/s12916-024-03257-7
[8]

Chen X, Wang D, Liu J, Qiu J, Zhou J, et al. 2021. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. Journal for Immunotherapy of Cancer 9:e003214

doi: 10.1136/jitc-2021-003214
[9]

Ni J, Li C, Xu X, Xu Q, Yin Q, et al. 2025. Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers. BMC Medicine 23:435

doi: 10.1186/s12916-025-04263-z
[10]

Skoulidis F, Heymach JV. 2019. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nature Reviews Cancer 19:495−509

doi: 10.1038/s41568-019-0179-8
[11]

Budczies J, Romanovsky E, Kirchner M, Neumann O, Blasi M, et al. 2024. KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma. British Journal of Cancer 131:524−33

doi: 10.1038/s41416-024-02746-z
[12]

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, et al. 2018. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discovery 8:822−835

doi: 10.1158/2159-8290.CD-18-0099
[13]

Rosner S, Connor S, Sanber K, Zahurak M, Zhang T, et al. 2025. Divergent clinical and immunologic outcomes based on STK11 co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade. Clinical Cancer Research 31:339−351

doi: 10.1158/1078-0432.CCR-24-2983
[14]

Nunes L, Stenersen JM, Kryeziu K, Sjöblom T, Glimelius B, et al. 2024. Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer. Molecular Cancer 23:264

doi: 10.1186/s12943-024-02173-x
[15]

Diehl AC, Hannan LM, Zhen DB, Coveler AL, King G, et al. 2022. KRAS mutation variants and co-occurring PI3K pathway alterations impact survival for patients with pancreatic ductal adenocarcinomas. The Oncologist 27:1025−1033

doi: 10.1093/oncolo/oyac179
[16]

Harvey-Jones E, Raghunandan M, Robbez-Masson L, Magraner-Pardo L, Alaguthurai T, et al. 2024. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. Annals of Oncology 35:364−380

doi: 10.1016/j.annonc.2024.01.003
[17]

Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, et al. 2024. Co-occurring BRCA2/SPOP mutations predict exceptional poly (ADP-ribose) polymerase inhibitor sensitivity in metastatic castration-resistant prostate cancer. European Urology Oncology 7:877−887

doi: 10.1016/j.euo.2023.11.014
[18]

Li XM, Li WF, Lin JT, Yan HH, Tu HY, et al. 2021. Predictive and prognostic potential of TP53 in patients with advanced non-small-cell lung cancer treated with EGFR-TKI: analysis of a phase III randomized clinical trial (CTONG 0901). Clinical Lung Cancer 22:100−109.e3

doi: 10.1016/j.cllc.2020.11.001
[19]

Hanker AB, Brown BP, Meiler J, Marín A, Jayanthan HS, et al. 2021. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell 39:1099−1114.e8

doi: 10.1016/j.ccell.2021.06.001
[20]

Su D, Zhang D, Chen K, Lu J, Wu J, et al. 2017. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods. Journal of Experimental & Clinical Cancer Research 36:121

doi: 10.1186/s13046-017-0591-4
[21]

Xiao Y, Lu D, Lei M, Xie W, Chen Y, et al. 2021. Comprehensive analysis of DNA damage repair deficiency in 10, 284 pan-cancer study. Annals of Translational Medicine 9:1661

doi: 10.21037/atm-21-5449
[22]

Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, et al. 2018. Tumor mutation burden as a biomarker in resected non-small-cell lung cancer. Journal of Clinical Oncology 36:2995−3006

doi: 10.1200/JCO.2018.78.1963
[23]

Wang D, Wang N, Li X, Chen X, Shen B, et al. 2021. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia. Gastric Cancer 24:823−834

doi: 10.1007/s10120-021-01175-8
[24]

Dao P, Kim YA, Wojtowicz D, Madan S, Sharan R, et al. 2017. BeWith: A Between-Within method to discover relationships between cancer modules via integrated analysis of mutual exclusivity, co-occurrence and functional interactions. PLoS Computational Biology 13:e1005695

doi: 10.1371/journal.pcbi.1005695
[25]

Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, et al. 2022. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Annals of Oncology 33:1269−1283

doi: 10.1016/j.annonc.2022.09.150
[26]

Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, et al. 2023. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. The Lancet Oncology 24:772−782

doi: 10.1016/S1470-2045(23)00242-5
[27]

Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, et al. 2020. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. The Lancet Oncology 21:671−684

doi: 10.1016/S1470-2045(20)30109-1
[28]

Hwang S, Woo S, Kang B, Kang H, Kim JS, et al. 2025. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. Journal of Hepatology 82:649−657

doi: 10.1016/j.jhep.2024.10.020
[29]

Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, et al. 2022. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Annals of Oncology 33:929−38

doi: 10.1016/j.annonc.2022.05.519
[30]

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, et al. 2020. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet Oncology 21:1353−1365

doi: 10.1016/S1470-2045(20)30445-9
[31]

Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, et al. 2024. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. The Lancet Oncology 25:707−719

doi: 10.1016/S1470-2045(24)00140-2
[32]

Wu Q, Ellis H, Siravegna G, Michel AG, Norden BL, et al. 2024. Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma. Clinical Cancer Research 30:198−208

doi: 10.1158/1078-0432.CCR-23-1317
[33]

Galan-Cobo A, Vokes NI, Qian Y, Molkentine D, Ramkumar K, et al. 2025. KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer Cell 43:1530−1548.e9

doi: 10.1016/j.ccell.2025.06.011
[34]

Westcott PMK, Muyas F, Hauck H, Smith OC, Sacks NJ, et al. 2023. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity. Nature Genetics 55:1686−1695

doi: 10.1038/s41588-023-01499-4
[35]

Beaudry F, Li Z, Borgida A, Zorigtbaatar A, Wang X, et al. 2025. Molecular tumor board-guided targeted treatments for biliary tract cancers in a publicly funded healthcare system. Current Oncology 32:80

doi: 10.3390/curroncol32020080
[36]

Zhang D, Dorman K, Heinrich K, Weiss L, Boukovala M, et al. 2023. A retrospective analysis of biliary tract cancer patients presented to the molecular tumor board at the comprehensive cancer center munich. Targeted Oncology 18:767−776

doi: 10.1007/s11523-023-00985-3
[37]

Kawamoto Y, Morizane C, Komatsu Y, Kondo S, Ueno M, et al. 2024. Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. Future Oncology ; 20:1901−1907

doi: 10.2217/fon-2023-0348
[38]

Gross AM, O'Sullivan Coyne G, Dombi E, Tibery C, Herrick WG, et al. 2025. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. Nature Medicine 31:105−115

doi: 10.1038/s41591-024-03361-4
[39]

Jiang M, Zhang K, Zhang Z, Zeng X, Huang Z, et al. 2025. PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment. MedComm 6:e70295

doi: 10.1002/mco2.70295
[40]

Shi R, Wang X, Wu Y, Xu B, Zhao T, et al. 2022. APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases. Theranostics 12:4181−4199

doi: 10.2139/ssrn.4062750
[41]

DiMarco AV, Qin X, McKinney BJ, Garcia NMG, Van Alsten SC, et al. 2022. APOBEC mutagenesis inhibits breast cancer growth through induction of T cell-mediated antitumor immune responses. Cancer Immunology Research 10:70−86

doi: 10.1158/2326-6066.CIR-21-0146